RANIBIZUMAB
ranibizumab 1.65 mg/0.165 mL injection, 0.165 mL syringe
RANIBIZUMAB (10138N)
10138N
Body System:
Manner of administration:Injection
Restriction
Indication: Subfoveal choroidal neovascularisation (CNV)
Treatment phase: Initial treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 2 | DPMQ: $786.69 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
|
|
|||||